SKYE
Skye Bioscience Inc.
$0.71
$0.00(0.00%)
48
Overall
60
Value
36
Tech
--
Quality
Market Cap
$46.79M
Volume
114.83K
52W Range
$0.57 - $5.75
Target Price
$8.71
Company Overview
| Mkt Cap | $46.79M | Price | $0.71 |
| Volume | 114.83K | Change | +0.00% |
| P/E Ratio | -1.8 | Open | $0.70 |
| Revenue | -- | Prev Close | $0.71 |
| Net Income | $-26.6M | 52W Range | $0.57 - $5.75 |
| Div Yield | N/A | Target | $8.71 |
| Overall | 48 | Value | 60 |
| Quality | -- | Technical | 36 |
No chart data available
About Skye Bioscience Inc.
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company's lead product candidate is nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, which is in Phase 2 clinical trial. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Sector: Industrials
Industry: General Freight Trucking, Long-Distance, Truckload
Latest News
Analysts Offer Insights on Healthcare Companies: Skye Bioscience (SKYE) and Sandoz Group Ltd (OtherSDZXF)
Brian Anderson•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SKYE | $0.71 | 0% | 114.83K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |